Pear Bio

Pear Bio is a biotechnology company that tests cancer treatment efficacy directly on patient-derived tumour samples using three-dimensional immune-microtumour cultures and computer vision analysis.

By culturing tumour biopsies with matched patient immune cells and imaging drug effects over time, the platform generates functional biomarkers to predict individual treatment response, independent of genomic profiling.

The company runs clinical trials across NHS sites and uses data from non-responding patients to drive an internal oncology drug discovery pipeline.